Chinese innovative drugs developer Allist Pharmaceuticals announced on Thursday that it has raised RMB1.18 billion (US$170.75 million) in a new funding round led by healthcare-focused private equity firm Shiyu Capital.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?